NasdaqCM:DNTHBiotechs
Should Dianthus Therapeutics’ (DNTH) Big Cash Raise and LBL-047 Bet Prompt Investor Reassessment?
Nanjing Leads Biolabs Co. Ltd. recently announced that partner Dianthus Therapeutics selected Sjögren's disease, systemic lupus erythematosus, and dermatomyositis as priority indications for LBL-047, while Dianthus also reported a wider first-quarter 2026 net loss of US$40.83 million alongside an upsized public offering that raised about US$719 million.
The decision to advance LBL-047, a bifunctional fusion protein targeting both pDC-driven Type 1 interferon and BAFF/APRIL B‑cell pathways,...